Data protection
Your personal data will be used strictly for organisational purposes. Please refer to our privacy policy for further information.

Processing...

Biomarkers for precision therapy and prevention of type 2 diabetes

17 September 2021 | 14—17.30 CEST | Online Meeting

By defining novel biomarkers for an improved taxonomy of type 2 diabetes and its progression, RHAPSODY intends to open up new roads towards diabetes prevention and treatment, and accelerate the development of personalised diabetes care.

In the end of the project, the RHAPSODY team is eager to share its achievements with patient and healthcare communities and welcomes all to a half-day symposium on September 17, 2021.

Agenda

Time
Title
Speaker
13.30
Online reception
14.00
Welcome
Bernard Thorens
RHAPSODY academic coordinator, Lausanne
14.05
Diabetes care – a clinician`s point of view
Andreas Festa
Eli Lilly, diabetologist
14.20
Diabetes care - a patient's perspective
Laying the foundations for targeted prevention and treatments for people living with type2 diabetes and those at risk
Elizabeth Robertson
Diabetes UK,
patient advocate
14.35
What does the Innovative Medicines Initiative do to help patients with diabetes?
Claire Varin
RHAPSODY industry coordinator, Servier Paris
14.45
The RHAPSODY project:
Biomarkers in type 2 diabetes
Bernard Thorens
RHAPSODY academic coordinator, Lausanne
15.15
Break
15.45
A new diabetes patient sub-classification: what's next?
Emma Ahlqvist
Lund University Diabetes Centre
16.00
A new diabetes patient sub-classification: its application in RHAPSODY
Roderick Slieker
Leiden University Medical Center
16.15
Panel discussion
"Why does it matter?"
Moderator: Andreas Festa
Participants:
Claire Varin, Bernard Thorens, Anders Ekholm, Elizabeth Robertson, Steven Kahn (University of Washington, RHAPSODY scientific advisor)
17.15
Wrap-up, conclusions and open discussion
Claire Varin,
Bernard Thorens
17.30
End of the meeting

Other information


» Free of charge
» Registration mandatory
» Online-only meeting
Stacks Image 47
Stacks Image 398
Stacks Image 51
Stacks Image 349
This project receives funding from the Innovative Medicines Initiative 2 Joint Undertaking (www.imi.europa.eu) under grant agreement No 115881. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

This work is supported by the Swiss State Secretariat for Education‚ Research and Innovation (SERI) under contract number 16.0097-2.

The opinions expressed and arguments employed herein do not necessarily reflect the official views of these funding bodies.